CORALL Study

Comparison of Efficacy and Safety of Rosuvastatin Versus Atorvastatin in Type-2 diabetes patients

Objective

To compare the lipid lowering effects of rosuvastatin with atorvastatin in type-2 diabetics.

Patient Population

N=265; patients with dyslipidemia and type-2 diabetes.

Study Design

Patients were randomized to receive rosuvastatin 10 mg or atorvastatin 10 mg.
Doses were forced titrated (10-20-40 mg Rosuvastatin and 10-20-40-80 mg Atorvastatin) every 6 weeks until maximum doses were attained.

Results

Rosuvastatin gave significantly greater reduction of ApoB/ApoA1 ratio, total-C, LDL-C and Non HDL-C as compared to atorvastatin.

Safety

Rosuvastatin and atorvastatin were well tolerated.
The most common side-effect was myalgia, which occurred in 5% of rosuvastatin group and in 11% of atorvastatin group.

Conclusion

In subjects with type-2 diabetes, greater improvements of ApoB/ApoA1 ratio and lipid profile was observed with rosuvastatin as compared to atorvastatin.

J Intern Med 2005; 257: 531-9